Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes
NCT02240706
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
27
Enrollment
INDUSTRY
Sponsor class
Conditions
Myelodysplastic Syndromes
Interventions
PROCEDURE:
Best Supportive Care
DRUG:
BI 836858
Sponsor
Boehringer Ingelheim